[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR077546A1 - Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos - Google Patents

Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos

Info

Publication number
AR077546A1
AR077546A1 ARP100102373A ARP100102373A AR077546A1 AR 077546 A1 AR077546 A1 AR 077546A1 AR P100102373 A ARP100102373 A AR P100102373A AR P100102373 A ARP100102373 A AR P100102373A AR 077546 A1 AR077546 A1 AR 077546A1
Authority
AR
Argentina
Prior art keywords
weight
composition
cyanoquinoline
methoxy
microcrystalline cellulose
Prior art date
Application number
ARP100102373A
Other languages
English (en)
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of AR077546A1 publication Critical patent/AR077546A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente proporciona composiciones solidas que comprenden una 3-cianoquinolina, SKI-606, y que comprenden adicionalmente croscarmelosa sodica, Tween, o ambos. Reivindicacion 1: Una composicion farmacéuticamente aceptable que comprende: componentes intragranulares (a) 20-80 por ciento en peso de 4-(2,4-dicloro-5-metoxi-fenilamino)-6-metoxi-7-[3-(4-metil-piperazin-1-iI)-propoxi]-quinolin-3-carbonitrilo basado en el peso de la composicion; (b) povidona; (c) celulosa microcristalina; (d) 0,25-5 por ciento en peso de croscarmelosa sodica basado en el peso de la composicion; (e) poloxámero y componentes extraganulares; (f) celulosa microcristalina; y (g) estearato de magnesio. Reivindicacion 19: La composicion de acuerdo con la reivindicacion 1 o la reivindicacion 11, en forma de un comprimido granulado en humedo, revestido con una película, o en forma de un comprimido revestido en recipiente. Reivindicacion 20: Un procedimiento para tratar el cáncer que comprende administrar una cantidad eficaz de una composicion de acuerdo con la reivindicacion 1 o la reivindicacion 11.
ARP100102373A 2009-07-02 2010-07-02 Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos AR077546A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22253709P 2009-07-02 2009-07-02

Publications (1)

Publication Number Publication Date
AR077546A1 true AR077546A1 (es) 2011-09-07

Family

ID=42732381

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102373A AR077546A1 (es) 2009-07-02 2010-07-02 Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos

Country Status (15)

Country Link
EP (1) EP2448563A2 (es)
JP (1) JP2011012063A (es)
KR (1) KR20120046216A (es)
CN (1) CN102470109A (es)
AR (1) AR077546A1 (es)
AU (1) AU2010266342A1 (es)
BR (1) BRPI1015941A2 (es)
CA (1) CA2766067A1 (es)
IL (1) IL217298A0 (es)
MX (1) MX2012000048A (es)
RU (1) RU2011152105A (es)
SG (1) SG177309A1 (es)
TW (1) TW201113050A (es)
WO (1) WO2011002857A2 (es)
ZA (1) ZA201200366B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
MX365008B (es) 2008-06-17 2019-05-20 Wyeth Llc Combinaciones antineoplasticas que contienen hki-272 y vinorelbina.
EP4424375A2 (en) 2008-08-04 2024-09-04 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
PL2498756T5 (pl) 2009-11-09 2023-04-17 Wyeth Llc Preparaty maleinianu neratynibu w postaci tabletki
CA2780332C (en) 2009-11-09 2018-01-30 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
CN104447541A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 博舒替尼化合物
CN105384686B (zh) * 2014-09-04 2019-07-26 连云港润众制药有限公司 一种博舒替尼结晶方法
US20190060325A1 (en) * 2016-04-08 2019-02-28 Shionogi & Co., Ltd. Stabilized solid dosage form
US11247805B2 (en) 2017-03-31 2022-02-15 Nissei Asb Machine Co., Ltd. Resin container

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US20050163835A1 (en) * 2002-02-26 2005-07-28 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
CN1835923A (zh) 2003-08-19 2006-09-20 惠氏控股公司 制备4－氨基－3－喹啉腈的方法
AU2005283422C1 (en) * 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
ES2449197T5 (es) * 2005-07-01 2022-04-28 Wyeth Llc Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3- quinolincarbonitrilo y procedimientos de preparación de las mismas
WO2008053295A2 (en) * 2006-10-30 2008-05-08 Wockhardt Research Centre Pharmaceutical compositions of benzoquinolizine-2-carboxylic acid
CN101224185A (zh) * 2007-12-11 2008-07-23 山东蓝金生物工程有限公司 一种治疗实体肿瘤的伯舒替尼缓释植入剂

Also Published As

Publication number Publication date
RU2011152105A (ru) 2013-08-10
ZA201200366B (en) 2012-10-31
WO2011002857A3 (en) 2011-03-10
CN102470109A (zh) 2012-05-23
JP2011012063A (ja) 2011-01-20
MX2012000048A (es) 2012-01-27
WO2011002857A2 (en) 2011-01-06
AU2010266342A1 (en) 2012-01-19
EP2448563A2 (en) 2012-05-09
BRPI1015941A2 (pt) 2016-04-19
KR20120046216A (ko) 2012-05-09
CA2766067A1 (en) 2011-01-06
SG177309A1 (en) 2012-02-28
IL217298A0 (en) 2012-02-29
TW201113050A (en) 2011-04-16

Similar Documents

Publication Publication Date Title
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
BR112012024019A2 (pt) forma de dosagem de liberação controlada, e, método para liberar uma droga
CO6400186A2 (es) Tabletas de acetato de ulipristal
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
AR078952A1 (es) Formulaciones de comprimidos revestidos
CL2013000713A1 (es) Compuestos pirazin-2-cabonil-imino-1,3,8-triaza-espiro-[4.5]-decan-sustituidos, bloqueadores del canal de sodio epitelial (enac); composicion farmaceutica que los incluye; metodo de prevencion o tratamiento; y su uso para tratar una enfermedad o condicion mediada por el bloqueo del canal de sodio epitelial.
CO2018005842A2 (es) Composición farmacéutica que comprende un potente inhibidor de urat 1
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
RS54329B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMINE, PROCEDURES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
CU24619B1 (es) Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración por via oral
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
AR100977A1 (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
AR099385A1 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
PE20131035A1 (es) Formulacion de nevirapina de liberacion prolongada
PE20151607A1 (es) Formulaciones de compuestos organicos
PH12016500693B1 (en) Slow-release solid oral compositions
AR094146A1 (es) Unidad solida con alto contenido en fexofenadina y su procedimiento de preparacion
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal